AGMT Lung Cancer Registry
Short title: AGMT_LungCa Registry
Title: AGMT Lung Cancer Registry
Start: August 2020
Coordinating Investigator: Univ. Prof. Dr. Richard Greil
NIS Number: NIS009428
Number of patients: 500 (planned)
Sponsor: AGMT gemeinnützige GmbH
This registry is designed as multicenter observational cohort of patients with lung cancer. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.
For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient’s medical chart, is transferred to the electronic Case Report Forms.
About 500 patients will be included in this registry. This number may be revised over time as interest and demand dictates. This registry will initially start with 3 sites and shall then be extended throughout Austria.
The registry will be made available for all disciplines and physicians caring for cancer patients and will include patients ≥ 18 years with locally advanced or metastatic lung cancer (advanced or metastatic stage patients in Austria (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC).
- To describe the general characteristics of advanced or metastatic stage patients in Austria
- Molecular testing in patients with advanced or metastatic lung cancer
- Characterize subgroups
- Treatment and outcome of treatment
- OS, PFS
- Toxicity with a focus on immune related adverse events
Physicians will select appropriate patients for enrollment. Appropriate patients are expected to:
- Age ≥ 18 years, all sexes
- Diagnosis of locally advanced or metastatic lung cancer (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC)
- Be willing to provide informed consent
Due to the non-interventional design of this program there are no specific in- or exclusion criteria.